- Home
- CLPR vs ALGS Comparison
CLPR vs ALGS Comparison
Compare CLPR & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLPR
- ALGS
- Stock Information
- Founded
- CLPR 2015
- ALGS 2018
- Country
- CLPR United States
- ALGS United States
- Employees
- CLPR N/A
- ALGS N/A
- Industry
- CLPR Real Estate Investment Trusts
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- CLPR Real Estate
- ALGS Health Care
- Exchange
- CLPR Nasdaq
- ALGS Nasdaq
- Market Cap
- CLPR 57.5M
- ALGS 53.0M
- IPO Year
- CLPR 2017
- ALGS 2020
- Fundamental
- Price
- CLPR $4.28
- ALGS $9.47
- Analyst Decision
- CLPR
- ALGS Strong Buy
- Analyst Count
- CLPR 0
- ALGS 2
- Target Price
- CLPR N/A
- ALGS $60.00
- AVG Volume (30 Days)
- CLPR 81.7K
- ALGS 73.3K
- Earning Date
- CLPR 10-30-2025
- ALGS 11-05-2025
- Dividend Yield
- CLPR 8.70%
- ALGS N/A
- EPS Growth
- CLPR N/A
- ALGS N/A
- EPS
- CLPR N/A
- ALGS N/A
- Revenue
- CLPR $154,103,000.00
- ALGS $3,174,000.00
- Revenue This Year
- CLPR N/A
- ALGS N/A
- Revenue Next Year
- CLPR N/A
- ALGS $28.79
- P/E Ratio
- CLPR N/A
- ALGS N/A
- Revenue Growth
- CLPR 7.69
- ALGS N/A
- 52 Week Low
- CLPR $3.39
- ALGS $3.76
- 52 Week High
- CLPR $7.12
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- CLPR 53.34
- ALGS 45.20
- Support Level
- CLPR $4.27
- ALGS $10.66
- Resistance Level
- CLPR $4.52
- ALGS $11.65
- Average True Range (ATR)
- CLPR 0.17
- ALGS 0.84
- MACD
- CLPR -0.02
- ALGS -0.17
- Stochastic Oscillator
- CLPR 21.43
- ALGS 1.40
About CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.